Harahap Yahdiana, Noer Roesytas Fitria, Simorangkir Timbul Partogi H
Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
Pharmacy Study Program, Faculty of Medicine and Health Sciences, the Republic of Indonesia Defense University, Bogor, Indonesia.
Front Med (Lausanne). 2023 May 5;10:1022605. doi: 10.3389/fmed.2023.1022605. eCollection 2023.
Favipiravir and remdesivir are drugs to treat COVID-19. This study aims to find an optimum and validated method for simultaneous analysis of favipiravir and remdesivir in Volumetric Absorptive Microsampling (VAMS) by Ultra High-Performance Liquid Chromatography-Tandem Mass Spectrophotometry. The use of VAMS can be an advantage because the volume of blood is small and the sample preparation process is simple. Sample preparation was done by precipitation of protein using 500 μL of methanol. Analysis was carried out by ultra high-performance liquid chromatography-tandem mass spectrophotometry with ESI+ and MRM with m/z 157.9 > 112.92 for favipiravir, 603.09 > 200.005 for remdesivir, and at m/z 225.968 > 151.991 for acyclovir as the internal standard. The separation was carried out using an Acquity UPLC BEH C column (100 × 2.1 mm; 1.7 m), 0.2% formic acid-acetonitrile (50:50), flow rate was 0.15 mL/min, and column temperature was 50°C. The analytical method has been validated with the requirements issued by the Food and Drug Administration (2018) and European Medicine Agency (2011). The calibration range of favipiravir is 0.5-160 μg/mL and 0.002-8 μg/mL for remdesivir.
法匹拉韦和瑞德西韦是治疗新冠肺炎的药物。本研究旨在找到一种优化且经过验证的方法，通过超高效液相色谱 - 串联质谱法同时分析体积吸收微采样（VAMS）中的法匹拉韦和瑞德西韦。使用VAMS可能具有优势，因为采血量少且样品前处理过程简单。样品前处理通过用500μL甲醇沉淀蛋白质来完成。分析采用超高效液相色谱 - 串联质谱法，电喷雾电离正离子模式（ESI +）和多反应监测（MRM），法匹拉韦的质荷比为m/z 157.9＞112.92，瑞德西韦为603.09＞200.005，以阿昔洛韦质荷比m/z 225.968＞151.991作为内标。分离使用Acquity UPLC BEH C柱（100×2.1mm；1.7μm），0.2%甲酸 - 乙腈（50:50），流速为0.15mL/min，柱温为50℃。该分析方法已按照美国食品药品监督管理局（2018年）和欧洲药品管理局（2011年）发布的要求进行了验证。法匹拉韦的校准范围为0.5 - 160μg/mL，瑞德西韦为0.002 - 8μg/mL。
